Compare Amphastar Pharmaceuticals Inc (AMPH) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs DENTSPLY SIRONA Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while DENTSPLY SIRONA Inc trades at $12.26 (market cap $2.46B). The key difference: DENTSPLY SIRONA Inc is far larger — about 3× Amphastar Pharmaceuticals Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | XRAY | |
|---|---|---|
Market Cap | $826.08M | $2.46B |
Sector | Health | Health |
52-Week High | $30.81 | $16.85 |
52-Week Low | $16.87 | $9.64 |
Enterprise Value | $1.22B | $4.60B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Dentsply Sirona (XRAY) trades at $12.26, up 3.11% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $598M in 2025, with negative profit margins and declining revenue trends. Recent news highlights distribution expansion and new AI product launches, while earnings have missed estimates for three consecutive quarters.
The outlook remains challenging with persistent losses and high debt levels, though analyst consensus suggests moderate upside to the $12.50 price target. Key risks include margin pressure and soft European demand, while potential catalysts include digital dentistry adoption and cost management under new CFO leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
